Announcement – Accelsiors joins PRI’s Board

Accelsiors is delighted to announce our new partnership with of the Pharmabiotic Research Institute and that our Director of Translational Science, Helene Cvejic Hogervorst joins to the Board members of PRI.

As a scientifically driven, global, full-service CRO, Accelsiors is pleased to be a partnering member of this main representative organization and leading professional network aimed at developing regulatory intelligence and representing the European Human Microbiome pharmaceutical supply chain. We are glad to join to this cooperation and work with PRI’s members together to unlock the potential of the Microbiotic Medicinal Products and translate it into safe, effective and commercially viable therapeutics.

About the PRI

The PRI is a non-profit, pro-industry group, dedicated to make Microbiotic Medicinal Products a therapeutic reality in Europe. The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. This association dedicated to helping its members conceive, develop, produce and market medicines and therapies based on the Human Microbiome. The PRI’s unique collaborative approach supports the registration of Microbiotic Medicinal Products at the European level and provide technical and regulatory intelligence for its members.

Find out more about the PRI: www.pharmabiotic.org